Evidence map›Paper›PMID 40201546›Full record

ArticleFrontiers in aging neuroscience2025

Targeting neuroplasticity: a viewpoint on a future research direction with Parkinson's disease-related fatigue.

Shijie Hao, Jianpeng Zou

Abstract read
In one paragraph

Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shijie HaoCollege of Rehabilitation Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Jianpeng ZouDepartment of Rehabilitation and Physiotherapy, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease-related fatigue has an insidious onset and complex pathomechanisms, causing many adverse effects on patients. In clinical practice, Parkinson's disease-related fatigue has not received sufficient attention, and its early diagnosis and targeted interventions are inadequate. Currently, pharmacological treatments for Parkinson's disease-related fatigue have limited efficacy and nonpharmacological therapies such as non-invasive brain stimulation techniques and exercise therapy have been shown to have a role in improving Parkinson's disease-related fatigue. Further studies have revealed that modulation of functional cortical excitability, induction of neuroplasticity changes, inhibition of oxidative stress, improvement of cardiorespiratory fitness, and enhancement of muscle strength may be potential mechanisms of action of non-pharmacological therapies. As relevant research continues to progress, targeted therapy based on the theory of neuroplasticity may become an important therapeutic idea for Parkinson's disease-related fatigue. This article provides an overview of the diagnosis, etiology, and treatment of Parkinson's disease-related fatigue, and on this basis proposes a new diagnostic and therapeutic idea of targeting neuroplasticity to improve Parkinson's disease-related fatigue for clinical reference. Further studies on the pathological mechanisms of Parkinson's disease-related fatigue are needed in the future to optimize the treatment regimen of Parkinson's disease-related fatigue to improve the efficacy of treatment for the benefit of patients.

Indexed as

brain-derived neurotrophic factorexercise therapyneuroplasticitynon-invasive brain stimulationParkinson’s disease-related fatigue

Identifiers

PMID40201546
PMCPMC11975876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.